key: cord-0924542-8rkffrkc authors: Manganotti, Paolo; Bellavita, Giulia; D'Acunto, Laura; Tommasini, Valentina; Fabris, Martina; Sartori, Arianna; Bonzi, Lucia; Buoite Stella, Alex; Pesavento, Valentina title: Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain‐Barré syndrome and polyneuritis cranialis in COVID‐19 patients: A case series date: 2020-07-27 journal: J Med Virol DOI: 10.1002/jmv.26289 sha: a8965c538fbfc0ccd8f4b47b009885c9db2395b7 doc_id: 924542 cord_uid: 8rkffrkc We report a case series of five patients affected by SARS‐CoV‐2 who developed neurological symptoms, mainly expressing as polyradiculoneuritis and cranial polyneuritis in the 2 months of COVID‐19 pandemic in a city in the northeast of Italy. A diagnosis of Guillain‐Barré syndrome was made on the basis of clinical presentation, cerebrospinal fluid analysis, and electroneurography. In four of them, the therapeutic approach included the administration of intravenous immunoglobulin (0.4 g/kg for 5 days), which resulted in the improvement of neurological symptoms. Clinical neurophysiology revealed the presence of conduction block, absence of F waves, and in two cases a significant decrease in amplitude of compound motor action potential compound muscle action potential (cMAP). Four patients presented a mild facial nerve involvement limited to the muscles of the lower face, with sparing of the forehead muscles associated to ageusia. In one patient, taste assessment showed right‐sided ageusia of the tongue, ipsilateral to the mild facial palsy. In three patients we observed albuminocytological dissociation in the cerebrospinal fluid, and notably, we found an increase of inflammatory mediators such as the interleukin‐8. Peripheral nervous system involvement after infection with COVID‐19 is possible and may include several signs that may be successfully treated with immunoglobulin therapy. Since December 2019, the novel coronavirus (SARS-CoV-2) has rapidly spread worldwide, causing an increased number of hospitalization and intensive care admissions, due to severe respiratory distress. Even though respiratory symptoms play a critical role in the clinical picture, in the last few weeks a variety of systemic manifestations has been increasingly described, including neurological symptoms. Neurological complications reported so far in patients affected by new coronavirus infectious disease (COVID-19) suggest a possible neurotropism of the virus and its potential ability to induce auto-immunity reactions. Several neurological complications have been described, including cerebrovascular accidents, polyradiculoneuritis (Guillain-Barré syndrome), and other inflammatory diseases. 1 Among the peripheral nervous system manifestations, the most frequently observed are hyposmia, hypogeusia, and Guillain-Barrè syndrome (GBS). 2,3 GBS is a heterogeneous condition with several variant forms: the most common presentation is the progressively ascending tetraparesis (acute inflammatory demyelinating polyneuropathy), but other localized clinical variants are also recognized. Miller-Fisher syndrome (MFS), a regional variant characterized by the triad of ophthalmoplegia, ataxia, and areflexia, has also been linked to According to a new classification, autoimmune neuropathies can also include forms with central nervous system involvement (Bickerstaff brainstem encephalitis). 5 About 60% of the above-mentioned autoimmune syndromes can be infection-related by humoral and cellular cross-reactivity, 6 ,7 most frequently gastrointestinal (Campylobacter jejuni) or respiratory tract infections, including flu syndrome and pneumonia. 8, 9 Clinical neurophysiology represents a fundamental tool for the diagnosis of acute inflammatory neuropathies. Neurophysiological investigations, however, require close contact with the patient and may result in an increased risk of infection, therefore, only partial data have been collected so far in COVID-19 patients. Here we report a case series of five patients affected by COVID-19 who developed a spectrum of autoimmune polyneuropathies during hospitalization. We describe their clinical features, laboratory testing as well as treatment response. Particular attention has been paid to neurophysiological findings and cerebrospinal fluid analysis. This case series described five patients admitted to the hospital affected by bilateral pneumonia due to SARS-CoV-2 infection from March to April 2020. Symptoms on admission were fever and cough, and in four out of five patients significant impairment of taste and smell was also reported (Table 1 ). Due to respiratory failure patients were admitted in the COVID-19 protected areas of the University Hospital of Trieste. COVID-19 diagnosis was then confirmed by means of nasopharyngeal swab. COVID-19 management included a variety of treatments, including antiviral drugs (Lopinavir/Ritonavir, Darunavir), hydroxychloroquine, antibiotic therapy, and oxygen support (Table 1) . Two patients received Tocilizumab, a monoclonal antibody targeting the interleukin (IL)-6 receptor. Two out of the five patients remained in COVID-dedicated internal medicine units, whereas three of them required mechanical ventilation in the intensive care unit (ICU) for a prolonged time (from 11 to 20 days). Patients developed progressive weakness of the upper and lower limbs, in a distoproximal fashion; the latency between the onset of the respiratory symptoms and neurological involvement ranged from 14 to 30 days. However, the longest latency (30 days) has been observed in a patient who came under prolonged sedation in ICU, therefore it is likely that symptoms appeared earlier in the course of the disease, but were not assessable at that time. All the patients received neurological examination at symptoms development, routine blood chemistry analyses, and a panel of antiganglioside antibodies, including anti-GM1, -GM2, -GM3, -GD1a, -GD1b, -GT1b, and -GQ1b, were performed according to standard procedures. Cerebrospinal fluid (CSF) was collected and processed for standard analyses including pressure, cell count, proteins, and glucose. CSF culture and polymerase chain reaction (PCR) for possible organisms, such as bacteria, Mycobacterium tuberculosis, fungi, Herpes viruses, Enteroviruses, Japanese B virus, and Dengue viruses, were performed, including analysis for SARS-CoV-2. Neurological examination revealed a flaccid paresis in four patients, with variable lower or upper limb predominance; interestingly, in these patients, we observed a unilateral mild facial nerve involvement limited to the muscles of the lower face, with sparing of the forehead muscles. Two patients also reported paresthesia, described as tingling or a sense of "tight bandage" located at the lower extremities. Deep tendon reflexes were diffusely absent. The fifth patient developed a slightly different clinical picture, characterized by bilateral ophthalmoplegia, hypoesthesia in the territory of maxillary and mandibular trigeminal branches, mild right lower facial nerve palsy, and limb ataxia. Generalized areflexia was also present. All patients have been complaining of taste and smell impairment since the beginning of the respiratory symptoms. In the latter patient described we performed a taste assessment which showed right-sided ageusia of the tongue, ipsilateral to the mild facial palsy Three patients showed the presence of conduction block mainly in lower limbs, two of them mainly in the upper limbs ( Table 2) . All the patients showed either an increase in latency of F wave or the dispersion and the decrease in amplitude of F wave. In two of them, we noted the presence of denervation signs related to the marked decrease amplitude of peroneal and tibial nerve suggesting axonal damage. In particular, the patients had a decrease in amplitude of the facial nerve conduction recorded from orbicularis oris and stimulated from the tragus site ipsilateral to the facial weakness. Notably, the nerve conduction recorded from orbicularis oculi was normal. The blink reflex was performed in one patient and was normal. 19 dedicated areas are the overriding concern. In our experience, ENG was mandatory for the correct diagnosis despite being complicated to perform in COVID-19 areas, to respect the protocols of security and protection. 10 In two of our patients, the ENG has documented the presence of conduction block and increase in latency and dispersion of F waves typical of GBS, while in the other two cases a significant decrease in amplitude in distal and proximal compound muscle action potential as previously reported in axon motor acute neuropathy. 5 In contrast, the ENG in the fifth patient was able to clearly detect the facial involvement. In this study, we observed an increase in serum ILs, particularly IL-6 and IL-8 in three patients; these findings are consistent with the current evidence that the overproduction of inflammatory cytokines may lead to severe forms of COVID-19, increased risk of multiorgan failure, and eventually death. 11 Indeed, in three of our patients, mechanical ventilation was required due to the acute respiratory distress syndrome, while two received Tocilizumab to block the inflammatory cascade. As such, the autoimmune polyneuropathies F I G U R E 1 a 50-year-old female with initial ophthalmoplegia and diplopia, left upper arm cerebellar dysmetria, generalized areflexia, mild defect in right lower branch of facial nerve. The facial defect persisted after the general improvement with immunoglobulins therapy. Asymmetry of the latency and amplitude of facial nerve conduction of the right lower branch was associated with asymmetrical ageusia for salt and sweet taste on the right side of the tongue | observed in our patients may be considered as part of a systemic overactive inflammatory response, namely "cytokine storm." Moreover, in two out of three patients tested, IL-8 resulted markedly increased also in CSF, with a CSF/serum ratio more than 1, suggesting the presence of an acute inflammatory process specifically targeting the nervous system. Previous studies showed that the CSF/ serum IL-8 ratio was increased in GBS as compared to chronic neuropathies such as the chronic inflammatory demyelinating polyneuropathy, thus it has been proposed as a possible biomarker of acute immune reaction against the nervous system. 12, 13 Neurological complications are common following respiratory infections, 8 The timing of neurological signs in one of our patients seemed too rapid to imply a typical heterologous immune reaction to a first viral exposure and it could rather resemble a form of acute parainfectious paralysis that has already been associated with some viruses, such as ZIKV. 20, 21 This paralysis usually develops from 5 to 10 days after infection and has higher morbidity, more frequently with cranial neuropathies and concurrent immune-mediated disorders such as thrombocytopenic purpura 9 ; antiglycolipids antibodies typically involved in cross-reactive mechanisms are not common. 9 We thank all the staff of the COVID-19 dedicated area and the neurophysiology technicians. The authors declare that there are no conflict of interests. PM contributed to conceptualization, study design, data collection, Neurological manifestations and complications of COVID-19: A literature review Neurologic features in severe SARS-CoV-2 infection Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2 Guillain-Barré and Miller-Fisher syndromes-new diagnostic classification Guillain-Barré syndrome after exposure to influenza virus Respiratory virus-induced heterologous immunity: part of the problem or part of the solution? The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respi Viruses Neurological complications during treatment of Middle East respiratory syndrome Practical guidance for managing EMG requests and testing during the COVID-19 pandemic COVID-19 cytokine storm: the interplay between inflammation and coagulation The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy IL-8 as a potential biomarker in Guillain-Barre Syndrome Neurologic manifestations of hospitalized patients with coronavirus disease Anti-ganglioside complex antibodies in Miller-Fisher syndrome How often and when Fisher syndrome is overlapped by Guillain-Barré syndrome or Bickerstaff brainstem encephalitis? Anti-ganglioside antibody-negative Miller Fisher and AMSAN variant Guillain-Barré Overlap Syndrome Nervous system involvement after infection with COVID-19 and other coronaviruses Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms Zika virus infection-after the pandemic Zika virus infection and Guillain-Barré syndrome: a review focused on clinical and electrophysiological subtypes Guillain-Barré syndrome with unilateral peripheral facial and bulbar palsy in a child: acase report Polyneuritis cranialis: clinical and electrophysiological findings Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain-Barré syndrome and polyneuritis cranialis in COVID-19 patients: A case series http://orcid.org/0000-0001-5305-6268Alex Buoite Stella https://orcid.org/0000-0002-4871-7022